Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center, discusses how a patient’s age can affect their glaucoma symptoms and treatment.
As patients live longer, ophthalmologists need to revisit the notion that older patients may not need as aggressive treatment for glaucoma as younger patients, said Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center.
Transcript
Can you introduce yourself and explain your work?
My name is Leon Herndon, professor of ophthalmology at the Duke University Eye Center, where I'm the chief of the glaucoma division. My passion really deals with taking care of glaucoma patients and teaching the next generation of glaucoma specialists.
How can a patient's age impact the diagnosis and treatment of primary open-angle glaucoma?
Well, we know that the incidence of glaucoma increases as patients get older, and the population is getting older. We know that if you look at life table analysis, a 90-year-old patient has another 4 to 5 years to live. It really would be nice to know how long each patient will live, but we just don't have that ability to predict that. But from a lot of work out of the Duke Glaucoma Registry, we know that older patients tend to lose nerve fiber layer at a greater rate than younger patients. So, the classic teaching has been that the older the patient is, that we're not quite as aggressive with management of their glaucoma as we might be with a younger patient, who has many more years to live. But we need to revisit that. These older patients will live longer, and they may continue to lose vision if we don't pay attention to their intraocular pressures.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More